A trailblazer in psilocybin studies, Dr. Roland Griffiths passed away at age 77 on October 16, 2023, of colon cancer.
More than 24 years ago, Roland Griffiths, PhD, began a groundbreaking research program with a study that investigated the effects of high-doses of psilocybin in healthy volunteers in a controlled setting (1). With the results from this study and the many more studies on psilocybin that followed, he is credited as helping to bring psychedelics back into the field of research (1,2).
Dr. Griffiths began at Johns Hopkins in 1972, after earning his PhD from the University of Minnesota (1). He was a distinguished Professor in the Departments of Psychiatry and Neurosciences at Johns Hopkins University School of Medicine and his research, both in clinical and preclinical laboratories, included the effects of mood-altering drugs, caffeine, and other substances (3).
One of his several noteworthy studies was, “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance,” a double-blind study on the short- and long-term effects of a high dose of psilocybin, published in 2006 (4). “When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences,” concluded part of the abstract from the study (4). “The ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences.”
Dr. Griffiths authored more than 400 journal articles and chapters, and also trained more than 50 postdoctoral research fellows (3). His work received grants from the National Institute of Health (NIH), where he also served as a consultant (1,3).
“Although Dr. Griffiths will not be around to see all the fruits of his labor, his influence of his legacy will reverberate well beyond his passing,” wrote one article covering his life and accomplishments (5). “One of the psychedelic industry’s true shining lights.”
“A hallmark feature of [psychedelic] experiences is that we’re all in this together,” Dr. Griffiths stated earlier this year (1). “It opens people up to this sense that we have a commonality and that we need to take care of each other.”
References
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.